Laura M. Kidd Cordova
A trial attorney and former federal prosecutor, Laura Cordova draws on her experience to effectively represent individuals and companies in federal criminal and civil government enforcement actions and related complex litigation. Laura’s practice includes handling sensitive internal investigations, navigating high-stakes government investigations, and defending clients in complex criminal and civil litigation. Laura has broad experience representing clients across the healthcare industry in criminal and False Claims Act matters involving allegations of healthcare fraud, Anti-Kickback Statute violations, and procurement fraud.
While at DOJ in Washington, DC, Laura supervised dozens of healthcare fraud prosecutions around the country and led the Corporate Healthcare Fraud Strike Force, a group of experienced healthcare fraud prosecutors, who investigated and prosecuted large, multi-jurisdictional fraud schemes. In addition to her supervisory role at DOJ, Laura investigated and tried numerous complex cases, involving healthcare fraud, violations of the Anti-Kickback Statute, mail and wire fraud, money laundering, false statements, and government program fraud.
In addition to her legal practice, Laura serves as an adjunct professor of law at the University of Houston Law Center, where she teaches a course on health care fraud and abuse.
B.S., Texas A&M University
Master of Public Health, Johns Hopkins Bloomberg School of Public Health
J.D., Georgetown University Law Center
District of Columbia
U.S. District Court for the Southern, Eastern, and Western Districts of Texas
U.S. District Court for the Eastern and Southern Districts of New York
U.S. District Court for the Eastern District of Wisconsin
U.S. Court of Appeals for the Fifth Circuit
- Represented pharmacy chain in DOJ joint criminal and civil False Claims Act (FCA) investigation arising from qui tam complaint alleging improperly obtained prior authorizations and violations of the Anti-Kickback Statute
- Represented trade organization in DOJ joint criminal and civil FCA investigation related to health insurance premium assistance programs
- Represented nonprofit in DOJ FCA investigation related to pharmaceutical patient assistance programs
- Represented national hospital system in DOJ FCA investigation arising from qui tam actions filed in multiple districts alleging improper diagnosis of patients
- Represented global healthcare company in DOJ FCA investigation related to generic drug pricing
- Represented executive in DOJ FCA investigation related to drug pricing and alleged Anti-Kickback Statute violations
- Represented pharmaceutical sales representative in DOJ FCA investigation related to alleged off-label marketing and violations of the Anti-Kickback Statute
- Conducted internal investigation for national hospital system in response to internal whistleblower allegations of Anti-Kickback Statute violations and improper patient inducement, and advised system regarding disclosure obligations and potential FCA liability
- Conducted internal investigation related to billing code errors, and advised regional hospital system regarding disclosure obligations and potential FCA liability
- Represented Fortune 20 healthcare company in DOJ FCA investigation arising from qui tam complaint alleging company conspired with service-disabled veteran-owned small businesses to fraudulently obtain Veterans Affairs supply contracts
- Represented contractor in Defense Criminal Investigative Service (DCIS) investigation related to labor cost reporting
- Represented Fortune 50 government contractor in DCIS investigation regarding compliance with federal government contract cybersecurity requirements
- Represented financial services company in DOJ FCA investigation of allegations that company conspired with construction company to commit fraud on the Small Business Administration’s 8(a) program
- Conducted internal investigation and advised healthcare products distribution company regarding compliance, disclosure obligations, and potential FCA liability related to various federal government contracts, including pricing obligations, the Buy American Act, and the Trade Agreements Act
- Conducted internal investigation and advised health plan regarding compliance, disclosure obligations, and potential FCA liability related to California state contract requirements
Securities Fraud and Other White Collar Matters
- Represented hospital system in DOJ and state Attorney General investigations related to tax credits
- Conducted internal investigation for Fortune 10 company related to allegations of improper accounting practices at a South American subsidiary
- Conducted internal investigation and represented global agricultural commodity trading company in criminal DOJ and USDA investigation related to imported agricultural products
- Represented former CEO in DOJ and SEC securities fraud investigations and related derivative and class actions alleging accounting fraud
- Represented foreign-exchange trader charged with wire fraud for allegedly “front-running” a foreign exchange transaction
- The Best Lawyers in America (Woodward/White Inc.), Commercial Litigation, 2023
- Lawdragon 500 Leading Litigators in America, 2022
- Washington DC Super Lawyer, Super Lawyers by Thomson Reuters, 2020-2021
- Assistant Attorney General’s Award for Distinguished Service, 2015
- Health and Human Services Inspector General’s Award for Excellence in Fighting Fraud, Waste, and Abuse, 2016
- IRS Criminal Investigation’s Recognition for Outstanding Support of the IRS Criminal Investigation Mission, 2016
- FBI Director’s Certificate for Demonstrated Excellence in Successfully Prosecuting a Major Criminal Case, 2014
- “US Supreme Court to Decide Whether the Government Can Prove Knowledge When the Defendant’s Regulatory Interpretation Is “Objectively Reasonable”,” Jackson Walker Insights (January 2023)
- “U.S. Supreme Court to Decide Standard for DOJ Dismissal of Qui Tam Cases,” Jackson Walker Insights (June 2022)
- “What to Know About the Department of Justice’s Nationwide Crackdown on Healthcare Fraud,” Jackson Walker Insights (September 2021)
- “DOJ Moves to Dismiss 10 Kickback-Related False Claims Act Complaints Against Pharmaceutical Companies,” Pratt’s Government Contracting Law Report (April 2019)
- “DOJ Resets Bar for Corporate-Cooperation Credit and Shifts Emphasis in False Claims Act Cases from Individual Accountability to Monetary Recovery,” Westlaw Journal’s Government Contract (January 2019)
- “Are Government and Health Care Contracts the Exception That Swallows the Brand Memo’s Rule on FCA Enforcement?” Westlaw Journal’s Government Contract (October 2018)
- “Department of Justice Leadership Previews Reforms to False Claims Act Enforcement: Significant Incentives for Cooperation and Strong Compliance,” Pratt’s Government Contracting Law Report (October 2018)
- Moderator, “Litigation Challenges in Procurement Fraud Matters,” 10th Annual False Claims and Qui Tam Trial Institute (April 2022)
- “Healthcare Enforcement and Why Effective Corporate Compliance Matters,” International Association of Defense Counsel (IADC) 2020 Midyear Meeting (February 2020)
- “Healthcare Fraud Enforcement and Corporate Compliance,” 2019 National Asian Pacific American Bar Association (NAPABA) Convention (November 2019)
- “801 Recent Developments in Individual Criminal and Civil Culpability,” Health Care Compliance Association’s (HCCA) 4th Annual Healthcare Enforcement Compliance Conference (November 2018)
- “Developments in Individual Criminal and Civil Culpability Post-Yates Memorandum,” American Health Law Association (AHLA) Fraud and Compliance Forum (September 2018)
- “Deep-Dive into Reverse False Claims: Preparing for the Future of False Claims for MCOs,” American Conference Institute (ACI) Managed Care Disputes and Litigation Conference (May 2018)
- “Pricing Governance and Anticipating Fraud and Abuse Risks in Light of the Current Pricing Debate,” American Conference Institute (ACI) 18th Annual Conference on Fraud and Abuse (March 2018)
- “Expectations of the DOJ,” Society of Corporate Compliance and Ethics (SCCE) Boston Regional Compliance & Ethics Conference (March 2017)
- “Developments with the False Claims Act and Qui Tam Enforcement in Light of the Escobar Decision,” American Conference Institute (ACI) 17th Annual Conference on Fraud and Abuse in the Sale and Marketing of Drugs, Devices, and Medical Technology (March 2017)
- “A Spotlight on Recent Trends in Enforcement,” CBI’s 5th Annual Compliance Monitoring Forum (February 2017)
- “Program Effectiveness – What’s the Government Looking for in Your Compliance Program?” American Health Law Association (AHLA) Fraud and Compliance Forum (October 2016)
- “Understand Trends in Recent Enforcement Targets,” CBI’s 10th Annual Forum on Transparency and Aggregate Spend (Aug. 2016)
- “From the Boardroom to the Big House? How Corporate Compliance and Government Regulations Keep You Safe,” Memphis Bar Association (July 2016)
- “U.S. Department of Justice Healthcare Compliance Update,” Global Healthcare 10th International Pharmaceutical Compliance Congress (May 2016)
- “U.S. Healthcare Fraud Enforcement,” CBI’s 13th Annual Pharmaceutical Compliance Congress (April 2016)
- “Emerging Enforcement Trends in Healthcare,” American Bar Association (ABA) 30th Annual National Institute on White Collar Crime (March 2016)
In the News
- “Ex-Fed. Health Care Prosecutor Laura Cordova Discusses Whistleblower Suits, Their Future Under Trump,” Corporate Counsel (March 2017)
June 2, 2023Insights
For False Claims Act Cases, SCOTUS Says Courts Should Look at What Defendants Subjectively Knew at Time of Offense
The U.S. Supreme Court recently announced its ruling in United States Ex Rel Schutte v. SuperValu Inc., a case that will impact how corporations will defend themselves in False Claims Act (“FCA”) litigation. In a win for the government, the Court held that the knowledge element of the FCA concerns what a defendant knew at the time it submitted a claim, not what someone could have objectively known after-the-fact.
January 24, 2023Insights
US Supreme Court to Decide Whether the Government Can Prove Knowledge When the Defendant’s Regulatory Interpretation Is “Objectively Reasonable”
The United States Supreme Court granted certiorari in a pair of cases out of the Seventh Circuit that will finally resolve a longstanding circuit split on the question of “scienter” under the False Claims Act (FCA)—namely, whether a defendant can “knowingly” violate the FCA if the relevant legal requirement is ambiguous and the defendant’s conduct is otherwise “objectively reasonable.”
By Jennifer Freel, Laura M. Kidd Cordova, & Bethany Pickett Shah
November 17, 2022Newsletters
JW Diversity & Inclusion Newsletter – November 2022
View Jackson Walker’s November 2022 Diversity & Inclusion Newsletter, Perspectives.
October 7, 2022Attorney News
Jackson Walker Congratulates 36 Attorneys Named Among the Lawdragon 500 Leading Litigators in America
Jackson Walker announces the selection of 36 attorneys to Lawdragon’s inaugural list of the 500 leading litigators in America.
August 18, 2022Attorney News
‘The Best Lawyers in America’ Honors 214 Jackson Walker Attorneys in 2023 Edition, Including 11 “Lawyers of the Year” and 41 “Ones to Watch”
The Best Lawyers in America has recognized 214 Jackson Walker attorneys across 6 offices and 79 specialty practice areas in its 2023 edition, including 11 Lawyers of the Year and 41 Ones to Watch. Best Lawyers listings are based on an exhaustive peer review survey of thousands of attorneys who vote on the legal abilities of others in their practice areas.
July 7, 2022Newsletters
Labor & Employment Dispatch: July 2022
View the July 2022 edition of the Labor & Employment Dispatch.
June 28, 2022Insights
U.S. Supreme Court to Decide Standard for DOJ Dismissal of Qui Tam Cases
By Laura M. Kidd Cordova & Jennifer S. Freel
Does the federal government have the authority to dismiss a False Claims Act (FCA) suit after initially declining to intervene? And what standard should courts apply to a government motion to dismiss a whistleblower suit? On June 21, 2022, the Supreme Court granted certiorari in United States, ex rel. Polansky v. Executive Health Resources, Inc., a case examining whether the U.S. Department of Justice – after declining to prosecute a qui tam action – has the authority to dismiss the action, and if so, what standard applies to the motion to dismiss.
March 14, 2022Speaking Engagements
Laura Cordova to Moderate Panel on “Litigation Challenges in Procurement Fraud Matters”
The 10th Annual False Claims and Qui Tam Trial Institute will feature a panel moderated by Laura Cordova addressing qui tam cases involving procurement fraud.
October 5, 2021Newsletters
JW Diversity & Inclusion Newsletter – October 2021
View Jackson Walker’s October 2021 Diversity & Inclusion Newsletter, Perspectives.
September 29, 2021Insights
What to Know About the Department of Justice’s Nationwide Crackdown on Healthcare Fraud
By Laura Cordova, Erica Giese, & Daniela Mondragón
The Department of Justice (DOJ) has identified over $1 billion in fraud-related losses to government-funded healthcare programs and private insurers. In its recent announcement, the DOJ highlighted enforcement actions targeting four major categories of alleged fraud: telemedicine; COVID-19 relief funds; substance abuse treatment facilities, or “sober homes”; and illegal prescription and/or distribution of opioids.